menu

Keeping Pace in Lung Cancer: Improving Outcomes for Patients with RET-Positive NSCLC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Keeping Pace in Lung Cancer: Improving Outcomes for Patients with RET-Positive NSCLC

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    RET rearrangements occur in about 1 to 2% of non-small cell lung cancers. Comprehensive genomic testing is critical for identifying these patients and selecting the appropriate treatment option.  Find out the exciting progress that has been made with precision oncology in RET+ NSCLC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Mark A. Socinski, MD
    Executive Medical Director
    Advent Health Cancer Institute
    Orlando, FL

    Commercial Interest Speakers Bureau: AstraZeneca, BMS, Bayer, Genentech, Guardant Health, Novarti Contracted Research: AstraZeneca, Genentech, Molecular Partners, Spectrum

    Faculty:
    Vivek Subbiah, MD
    Associate Professor, Investigational Cancer Therapeutics
    The University of Texas MD Anderson Cancer Center
    Houston, TX 

    Contracted research: Abbvie, Agensys, Alfa-sigma, Altum, Amgen, Bayer, Berghealt, Blueprint Medicines, Boston Biomedical, Boston Pharmaceuticals, Celgene, D3, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharma, Incyte, Inhibrx, LOXO Oncology/Eli Lilly, Medimmune, Multivir, Nanocarrier, National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, Pfizer, Pharmamar, Roche/Genentech, Takeda, Turning Point Therapeutics, UT MD Anderson Cancer Center, Vegenics
    Advisory board/consultant: Blueprint medicines, Daiichi-Sankyo, Helsinn, Incyte, LOXO Oncology/ Eli Lilly, Medimmune, Novartis, QED Pharma, Relay Therapeutics, Signant Health

    Reviewers/Content Planners/Authors:

    • Nicole Fox, DNP, MSN-Ed., RN, OCN, has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify studies with practice-changing potential in the treatment of patients with RET-positive metastatic NSCLC
    • Select appropriate therapy for patients with RET-positive NSCLC 
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists, pulmonologists, pathologists, oncology nurse practitioners, physician assistants, oncology nurses, and oncology pharmacists

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15-minutes of Nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    This curriculum has been approved for .25 contact hours .025 CEUs by Global Learning Collaborative (GLC).  GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is JA0006235-0000-21-005-H01-P.  This learning activity is enduring based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from Blueprint Medicines Corporation and Genentech, Inc., a member of the Roche Group

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    RET rearrangements occur in about 1 to 2% of non-small cell lung cancers. Comprehensive genomic testing is critical for identifying these patients and selecting the appropriate treatment option.  Find out the exciting progress that has been made with precision oncology in RET+ NSCLC.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Mark A. Socinski, MD
    Executive Medical Director
    Advent Health Cancer Institute
    Orlando, FL

    Commercial Interest Speakers Bureau: AstraZeneca, BMS, Bayer, Genentech, Guardant Health, Novarti Contracted Research: AstraZeneca, Genentech, Molecular Partners, Spectrum

    Faculty:
    Vivek Subbiah, MD
    Associate Professor, Investigational Cancer Therapeutics
    The University of Texas MD Anderson Cancer Center
    Houston, TX 

    Contracted research: Abbvie, Agensys, Alfa-sigma, Altum, Amgen, Bayer, Berghealt, Blueprint Medicines, Boston Biomedical, Boston Pharmaceuticals, Celgene, D3, Dragonfly Therapeutics, Exelixis, Fujifilm, GlaxoSmithKline, Idera Pharma, Incyte, Inhibrx, LOXO Oncology/Eli Lilly, Medimmune, Multivir, Nanocarrier, National Comprehensive Cancer Network, NCI-CTEP, Northwest Biotherapeutics, Novartis, Pfizer, Pharmamar, Roche/Genentech, Takeda, Turning Point Therapeutics, UT MD Anderson Cancer Center, Vegenics
    Advisory board/consultant: Blueprint medicines, Daiichi-Sankyo, Helsinn, Incyte, LOXO Oncology/ Eli Lilly, Medimmune, Novartis, QED Pharma, Relay Therapeutics, Signant Health

    Reviewers/Content Planners/Authors:

    • Nicole Fox, DNP, MSN-Ed., RN, OCN, has nothing to disclose.
    • Nick Lombardi has no relevant relationships to report
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Colleen Resnick has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify studies with practice-changing potential in the treatment of patients with RET-positive metastatic NSCLC
    • Select appropriate therapy for patients with RET-positive NSCLC 
  • Target Audience

    This activity is designed to meet the educational needs of community oncologists, pulmonologists, pathologists, oncology nurse practitioners, physician assistants, oncology nurses, and oncology pharmacists

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 15-minutes of Nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    This curriculum has been approved for .25 contact hours .025 CEUs by Global Learning Collaborative (GLC).  GLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Number for this program is JA0006235-0000-21-005-H01-P.  This learning activity is enduring based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.  

  • Commercial Support

    This activity is supported by independent educational grants from Blueprint Medicines Corporation and Genentech, Inc., a member of the Roche Group

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule23 Jan 2022
Webpack App